524 related articles for article (PubMed ID: 23137508)
1. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.
Bishu K; Deswal A; Chen HH; LeWinter MM; Lewis GD; Semigran MJ; Borlaug BA; McNulty S; Hernandez AF; Braunwald E; Redfield MM
Am Heart J; 2012 Nov; 164(5):763-770.e3. PubMed ID: 23137508
[TBL] [Abstract][Full Text] [Related]
2. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.
Maisel AS; Shah KS; Barnard D; Jaski B; Frivold G; Marais J; Azer M; Miyamoto MI; Lombardo D; Kelsay D; Iqbal N; Taub PR; Kupfer K; Lee E; Clopton P; Zile M; Greenberg B
J Card Fail; 2016 Apr; 22(4):283-93. PubMed ID: 26433086
[TBL] [Abstract][Full Text] [Related]
3. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.
Tromp J; Khan MA; Klip IT; Meyer S; de Boer RA; Jaarsma T; Hillege H; van Veldhuisen DJ; van der Meer P; Voors AA
J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28360225
[TBL] [Abstract][Full Text] [Related]
4. Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study.
Savarese G; Donal E; Hage C; Oger E; Persson H; Daubert JC; Linde C; Lund LH;
Int J Cardiol; 2017 Jan; 226():65-70. PubMed ID: 27788392
[TBL] [Abstract][Full Text] [Related]
5. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
[TBL] [Abstract][Full Text] [Related]
6. Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach.
Kanagala P; Arnold JR; Singh A; Chan DCS; Cheng ASH; Khan JN; Gulsin GS; Yang J; Zhao L; Gupta P; Squire IB; Ng LL; McCann GP
PLoS One; 2020; 15(4):e0232280. PubMed ID: 32349122
[TBL] [Abstract][Full Text] [Related]
7. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
8. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
[TBL] [Abstract][Full Text] [Related]
9. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
Zile MR; Jhund PS; Baicu CF; Claggett BL; Pieske B; Voors AA; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
Circ Heart Fail; 2016 Jan; 9(1):. PubMed ID: 26754625
[TBL] [Abstract][Full Text] [Related]
10. The predictability of renin-angiotensin-aldosterone system factors for clinical outcome in patients with acute decompensated heart failure.
Nakada Y; Takahama H; Kanzaki H; Sugano Y; Hasegawa T; Ohara T; Amaki M; Funada A; Yoshida A; Yasuda S; Ogawa H; Anzai T
Heart Vessels; 2016 Jun; 31(6):925-31. PubMed ID: 25964073
[TBL] [Abstract][Full Text] [Related]
11. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
[TBL] [Abstract][Full Text] [Related]
12. Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction.
de Boer RA; Nayor M; deFilippi CR; Enserro D; Bhambhani V; Kizer JR; Blaha MJ; Brouwers FP; Cushman M; Lima JAC; Bahrami H; van der Harst P; Wang TJ; Gansevoort RT; Fox CS; Gaggin HK; Kop WJ; Liu K; Vasan RS; Psaty BM; Lee DS; Hillege HL; Bartz TM; Benjamin EJ; Chan C; Allison M; Gardin JM; Januzzi JL; Shah SJ; Levy D; Herrington DM; Larson MG; van Gilst WH; Gottdiener JS; Bertoni AG; Ho JE
JAMA Cardiol; 2018 Mar; 3(3):215-224. PubMed ID: 29322198
[TBL] [Abstract][Full Text] [Related]
13. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
14. Predictive Value of Collagen Biomarkers for Heart Failure With and Without Preserved Ejection Fraction: MESA (Multi-Ethnic Study of Atherosclerosis).
Duprez DA; Gross MD; Kizer JR; Ix JH; Hundley WG; Jacobs DR
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475876
[TBL] [Abstract][Full Text] [Related]
15. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
16. Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction.
Vergaro G; Aimo A; Prontera C; Ghionzoli N; Arzilli C; Zyw L; Taddei C; Gabutti A; Poletti R; Giannoni A; Mammini C; Spini V; Passino C; Emdin M
Int J Cardiol; 2019 Dec; 296():91-97. PubMed ID: 31443984
[TBL] [Abstract][Full Text] [Related]
17. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.
Krum H; Elsik M; Schneider HG; Ptaszynska A; Black M; Carson PE; Komajda M; Massie BM; McKelvie RS; McMurray JJ; Zile MR; Anand IS
Circ Heart Fail; 2011 Sep; 4(5):561-8. PubMed ID: 21750125
[TBL] [Abstract][Full Text] [Related]
18. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
19. Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction.
Abernethy A; Raza S; Sun JL; Anstrom KJ; Tracy R; Steiner J; VanBuren P; LeWinter MM
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29650706
[TBL] [Abstract][Full Text] [Related]
20. Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction.
Cui K; Huang W; Fan J; Lei H
Medicine (Baltimore); 2018 Sep; 97(36):e12277. PubMed ID: 30200170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]